This episode of the Beyond Biotech podcast explores the growing obesity crisis and the innovative treatments being developed. Alessandro Toniolo, CEO of Resalis Therapeutics, discusses how his company is taking a novel approach to obesity treatment.

Key Points:

Resalis Therapeutics is pioneering a groundbreaking obesity treatment that moves beyond appetite suppression to target fat metabolism at a cellular level. With promising early results, Reso10 could redefine how obesity is managed in the future.

• Obesity Epidemic & Economic Impact: One billion people worldwide are currently obese, with projections showing that by 2035, nearly half of the global population will be overweight or obese. The economic burden exceeds $2 trillion annually due to healthcare costs and reduced workforce productivity.
• Current Treatments & Their Limitations: Many existing treatments, such as GLP-1 agonists, focus on appetite suppression. While effective, these drugs can cause muscle loss and metabolic slowdown, often leading to weight regain after stopping treatment.
• Resalis Therapeutics' Innovative Approach: Resalis is developing Reso10, a drug that targets microRNA-22 (M22), regulating fat metabolism instead of suppressing appetite. It reduces fat storage, increases fat burning, and enhances mitochondrial function.
• How Reso10 Works: Unlike other treatments, Reso10 selectively burns excess fat while preserving muscle mass. It helps convert white fat (energy storage) into brown fat (energy-burning) and promotes long-term metabolic benefits.
• Clinical Trials & Future Prospects: The drug is currently in Phase 1 trials, testing safety in healthy volunteers. Phase 2 trials will focus on efficacy in overweight and obese individuals. If successful, Reso10 could offer a sustainable, long-term solution to obesity.
• The Future of Obesity Treatment: The obesity drug market is rapidly evolving, with pharmaceutical giants and biotech firms exploring new treatments. Resalis aims to establish Reso10 as a key player in this landscape, potentially complementing or surpassing current therapies.